Patents by Inventor ANDREAS RENE ROTHELI

ANDREAS RENE ROTHELI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof
    Publication number: 20240391897
    Abstract: Provided herein is a method for the manufacture of a compound of obicetrapib and salts thereof, such as calcium salts thereof. Also provided herein is amorphous obicetrapib hemicalcium. New intermediates for use in the synthesis of obicetrapib, and salts thereof are also provided, including obicetrapib HCl and a mesylate salt for the use in the synthesis of obicetrapib and amorphous obicetrapib hemicalcium.
    Type: Application
    Filed: April 16, 2024
    Publication date: November 28, 2024
    Inventors: Sheng CUI, Andreas René RÖTHELI, Christopher J. BORTHS, Muneki KISHIDA, Valeriya Nikolayevna SMOLENSKAYA
  • Salts of obicetrapib and processes for their manufacture and intermediates thereof
    Patent number: 12006305
    Abstract: Provided herein is a method for the manufacture of a compound of obicetrapib and salts thereof, such as calcium salts thereof. Also provided herein is amorphous obicetrapib hemicalcium. New intermediates for use in the synthesis of obicetrapib, and salts thereof are also provided, including obicetrapib HCl and a mesylate salt for the use in the synthesis of obicetrapib and amorphous obicetrapib hemicalcium.
    Type: Grant
    Filed: July 3, 2023
    Date of Patent: June 11, 2024
    Assignee: NewAmsterdam Pharma B.V.
    Inventors: Sheng Cui, Andreas René Rötheli, Christopher J. Borths, Muneki Kishida
  • Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof
    Publication number: 20240010630
    Abstract: Provided herein is a method for the manufacture of a compound of obicetrapib and salts thereof, such as calcium salts thereof. Also provided herein is amorphous obicetrapib hemicalcium. New intermediates for use in the synthesis of obicetrapib, and salts thereof are also provided, including obicetrapib HCl and a mesylate salt for the use in the synthesis of obicetrapib and amorphous obicetrapib hemicalcium.
    Type: Application
    Filed: July 3, 2023
    Publication date: January 11, 2024
    Inventors: Sheng CUI, Andrea René RÖTHELI, Christopher J. BORTHS, Muneki KISHIDA
  • ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES
    Publication number: 20240002400
    Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound IA, wherein R1 is described herein. Compound IA can be useful in synthesizing compound A1, or a salt or solvate thereof, and compound A2, or a salt of solvate thereof.
    Type: Application
    Filed: November 23, 2021
    Publication date: January 4, 2024
    Applicant: AMGEN INC.
    Inventors: KYLE D. BAUCOM, MICHAEL T. CORBETT, SHENG CUI, NEIL F. LANGILLE, ANDREAS RENE ROTHELI, ROBERTO PROFETA, AUSTIN G. SMITH
  • DIOL DESYMMETRIZATION BY NUCLEOPHILIC AROMATIC SUBSTITUTION
    Publication number: 20230365588
    Abstract: Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Y that can be used to prepare them where the variable R1 is as defined herein. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof, compound A2, and salts and solvates thereof, and compound A3 and salts and solvates thereof.
    Type: Application
    Filed: September 1, 2021
    Publication date: November 16, 2023
    Applicant: AMGEN INC.
    Inventors: MATTHEW G. BEAVER, JOSEPH MICHAEL DENNIS, PETER DORNAN, STEVEN MENNEN, JASON S. TEDROW, NEIL F. LANGILLE, CAROLYN MICHELLE COHEN, ANDREAS RENE ROTHELI